AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12941199
Drug: Inhibitors of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitors of vascular growth factor receptor (bevacizumab and PTK787)
Trial: 12941199
Drug: Cyclooxygenase‐2 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclooxygenase‐2 inhibitors in colorectal cancer and STI571 in GI stromal tumors
Trial: 12941199
Drug: Novel agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel agents administered alone or in combination with standard therapies
Trial: 10532418
Drug: Ki‐67 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ki‐67 antibody for cell proliferative activity
Trial: 1953228
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg twice a day for 8 weeks
Trial: 1953228
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg twice a day for an additional 8 weeks
Trial: 27914297
Drug: Vildagliptin add-on
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin add-on therapy
Trial: 27914297
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy without DPP-4 inhibitors
Trial: 25061034
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) and stretching exercise
Trial: 25061034
Drug: Intramuscular electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular electrical stimulation (IMS) and stretching exercise
Trial: 23093040
Drug: Adverse drug
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse drug events (ADEs)
Trial: 23093040
Drug: Other drug-related
RxNorm normalized name: OTHER DRUGS FOR ACID RELATED DISORDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drug-related problems (DRPs)
Trial: 23093040
Drug: Problems with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problems with administration and dosing of medicine
Trial: 18392557
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy with careful monitoring of INR
Trial: 10155208
Drug: Heparin-coated coronary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated coronary stents
Trial: 3038423
Drug: Enalapril 2.5
RxNorm normalized name: enalapril 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 2.5 to 10 mg once daily
Trial: 27069153
Drug: BCG instillation
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG instillation (one-third dose, three weekly instillations every 6 months for 3 years)
Trial: 27069153
Drug: BCG instillation
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG instillation (two weekly instillations every 3 months for 3 years)
Trial: 23733528
Drug: Medication diary-book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication diary-book
Trial: 23733528
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard parental education program and donated chemotherapy)
Trial: 20416246
Drug: Enema administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enema administered before surgery
Trial: 20416246
Drug: No enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No enema administered (Control)
Trial: 16548361
Drug: Yigong Zhixue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yigong Zhixue Oral Liquid, taken orally
Trial: 16548361
Drug: Yigong Zhixue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yigong Zhixue Oral Liquid
Trial: 2901815
Drug: Oral slow
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral slow release morphine 30 mg
Trial: 28776345
Drug: Daytime solifenacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daytime solifenacin dosing
Trial: 28776345
Drug: Nighttime solifenacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nighttime solifenacin dosing
Trial: 12452235
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg epidural morphine
Trial: 23921652
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg epidural morphine
Trial: 18371466
Drug: 12-month dual
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12-month dual antiplatelet therapy
Trial: 14664687
Drug: Treatment effects
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effects analysis
Trial: 8751803
Drug: TAM (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAM (30 mg/day) and MPA (800 mg/day)
Trial: 8751803
Drug: TAM (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAM (30 mg/day)
Trial: 8751803
Drug: MPA (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA (800 mg/day)
Trial: 30452719
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (mainly UFT)
Trial: 10441825
Drug: PLIF with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLIF with Moss-Miami implants
Trial: 2126002
Drug: Multi-drug combination
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-drug combination chemotherapy (VMCP)
Trial: 31093941
Drug: Clinical pharmacist
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacist led medication review using the RASP list
Trial: 21957592
Drug: Pain syndrome
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain syndrome therapy (Duloxetin and Gabapentin)
Trial: 19620930
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg/kg body weight + 0.125 g/kg carbohydrate)
Trial: 19620930
Drug: Placebo (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.125 g/kg carbohydrate)
Trial: 17225141
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg urapidil
Trial: 2969740
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg doxazosin
Trial: 15072419
Drug: Intratympanic buffer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic buffer solution (placebo)
Trial: 9060016
Drug: Phentolamine (alpha‐adrenoreceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (alpha‐adrenoreceptor antagonist)
Trial: 17917935
Drug: 5% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% imiquimod cream, 8 weeks of treatment with once‐daily dosing for alternate weeks (R1)
Trial: 17917935
Drug: 5% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% imiquimod cream, 5 weeks of once‐daily dosing with a 1‐week interval (R2)
Trial: 17313005
Drug: Diltiazem (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (oral administration)
Trial: 15297112
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral carbohydrate treatment (12.5%, 800 + 400 ml, n = 8)
Trial: 8157045
Drug: Terbutaline slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline slow-release 7.5 mg
Trial: 31657168
Drug: PGLA thread-embedding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGLA thread-embedding therapy combined with rehabilitation training
Trial: 28343601
Drug: RG7652 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7652 (1 of 5 doses)
Trial: 26489661
Drug: specialised Helping
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: specialised Helping Young People Early service model plus up to 16 sessions of individual cognitive analytic therapy
Trial: 24188276
Drug: Comprehensive traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comprehensive traditional Chinese medicine rehabilitation protocol
Trial: 19422296
Drug: AdoMet (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdoMet (800 mg per day) for 4 weeks
Trial: 11731184
Drug: Calcitonin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin and 1 alpha-hydroxycholecalciferol combination
Trial: 9095326
Drug: Combination regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimen
Trial: 11731184
Drug: Calcitonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin treatment
Trial: 9789699
Drug: Procainamide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procainamide (100 mg i.v. bolus every 5 min up to 1 g)
Trial: 9789699
Drug: Propafenone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (2 mg/kg body weight i.v. over 30 min)
Trial: 2585215
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 (5 mg intramuscularly)
Trial: 793777
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg amitriptyline as 3 daytime doses
Trial: 793777
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg amitriptyline as a single dose at bedtime
Trial: 31105976
Drug: Continuing prestroke
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing prestroke antihypertensives
Trial: 31105976
Drug: Stopping prestroke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping prestroke antihypertensives
Trial: 28809637
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment using plate osteosynthesis (LCP Distal Ulna Plate) for proximal third ulnar styloid process fractures, ulnar head fractures, and subcapital fractures.
Trial: 28809637
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for tip fractures of ulnar styloid process.
Trial: 28809637
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for ulnar base fractures.
Trial: 28809637
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment for subcapital ulnar fractures.
Trial: 28809637
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for ulnar head fractures.
Trial: 24529671
Drug: bupivacaine 10
RxNorm normalized name: BUPivacaine 100 mg parenteral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 10 mg combined with 0.1 mg/kg ketamine
Trial: 24529671
Drug: bupivacaine 10
RxNorm normalized name: BUPivacaine 100 mg parenteral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 10 mg combined with 0.5 mL distilled water
Trial: 23525044
Drug: Levodopa (L-DOPA)
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa (L-DOPA)
Trial: 9444592
Drug: Full-strength oxidizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-strength oxidizing lozenge
Trial: 9444592
Drug: Regular oxidizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular oxidizing lozenge
Trial: 3284282
Drug: Contingency contracting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency contracting for medication take-home privileges
Trial: 3284282
Drug: Contingency contracting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency contracting targeting non-cocaine drugs
Trial: 3284282
Drug: Non-drug-related contracts
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drug-related contracts
Trial: 31465756
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy plus dry needling (Ex+DN group)
Trial: 31465756
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (Ex group)
Trial: 27334604
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (group 1, n=76)
Trial: 21611981
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil 1200 mg once daily
Trial: 15159270
Drug: niacin ER/lovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin ER/lovastatin (1500/20 mg)
Trial: 15159270
Drug: niacin ER/lovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin ER/lovastatin (2000/40 mg)
Trial: 15159270
Drug: niacin ER
RxNorm normalized name: Niacin ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin ER (each 500 mg increase)
Trial: 15159270
Drug: niacin ER/lovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin ER/lovastatin (2000/40 mg/d)
Trial: 9737476
Drug: Enoxaparin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (1 mg/kg twice daily subcutaneously)
Trial: 9737476
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (continuous intravenous)
Trial: 7887165
Drug: Local specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local specific immunotherapy plus sodium cromoglycate
Trial: 7887165
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate and saline solution
Trial: 3580432
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg RS 86
Trial: 3580432
Drug: 3.0 mg
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg RS 86
Trial: 31821221
Drug: NEW Tx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEW Tx (Nutrition Exercise and Wellness Treatment)
Trial: 30875669
Drug: Control (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (treatment as usual waitlist)
Trial: 28527047
Drug: Dietary ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary ascorbic acid (50 mg/kg)
Trial: 28527047
Drug: Dietary ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary ascorbic acid (100 mg/kg)
Trial: 9544237
Drug: Intravenous gamma
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gamma globulin (IVIG) therapy
Trial: 7541325
Drug: rhG-CSF (Granulocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhG-CSF (Granulocyte Injection) with chemotherapy
Trial: 3824375
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg four times daily
Trial: 17407633
Drug: EZE +
RxNorm normalized name: Acetaminophen 650 MG Oral Tablet [PAIN-EZE +/RHEU-THRITIS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE + ATV (Ezetimibe 10 mg + Atorvastatin 10 mg)
Trial: 17407633
Drug: ATV (Atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV (Atorvastatin 10 mg)
Trial: 11095203
Drug: 15% glycolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% glycolic acid cream used once or twice daily for 24 weeks by 20 patients in Group B
Trial: 11095203
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied twice daily for 24 weeks by 15 patients in Group C
Trial: 9506004
Drug: Theophylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (5 mg/kg anhydrous, oral administration)
Trial: 8456071
Drug: Fast-disintegrating vitamin
RxNorm normalized name: vitamin B12 Disintegrating Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-disintegrating vitamin C tablet (8-9 min)
Trial: 8456071
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C tablet with a mean disintegration time of 60 min
Trial: 8456071
Drug: Standard vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard vitamin C solution
Trial: 2416520
Drug: Cimetidine treatment
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine treatment (1 g/day) for four weeks (standard treatment group)
Trial: 2416520
Drug: Cimetidine treatment
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine treatment (1 g/day) for a minimum of one week and thereafter until symptoms controlled (symptomatic treatment group)
Trial: 2416520
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment regimens (standard and symptomatic)
Trial: 2416520
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment group
Trial: 28922046
Drug: Supraorbital electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supraorbital electrical stimulation (SOES) in addition to conventional physical therapy (20 minutes daily for 8 weeks)
Trial: 28922046
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (3 times a week for 8 weeks)
Trial: 28922046
Drug: Prescribed medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed medications only
Trial: 17076946
Drug: Oral polyethylene
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral polyethylene glycol (PEG)
Trial: 22137497
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (300 μg daily)
Trial: 15781540
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% plus clonidine 2 microg/mL
Trial: 14519752
Drug: Screened arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Screened arm (prostate-specific antigen, digital rectal and transrectal ultrasound examinations)
Trial: 31853960
Drug: Lebrikizumab (anti-IL-13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab (anti-IL-13 monoclonal antibody)
Trial: 22311411
Drug: Comprehensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive therapy (CT) combining EA and PI for 40 days.
Trial: 9272472
Drug: Chiropractic management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic management (spinal manipulation, soft tissue therapy, passive stretching for 4 weeks)
Trial: 3205676
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (tablets)
Trial: 1972334
Drug: Enoximone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 0.5 mg kg‐1 as a bolus (n = 10)
Trial: 31189287
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate and benzydamine hydrochloride solution
Trial: 31189287
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and phosphate solution
Trial: 31189287
Drug: Black mulberry
RxNorm normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black mulberry syrup
Trial: 19439506
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with thyroid hormone (TH) including thyroxine and T(3) in prolonged critically ill rabbits
Trial: 17574679
Drug: Endothelial progenitor
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelial progenitor cells (EPCs) therapy
Trial: 16328638
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of oral celecoxib administered 30 min before surgery
Trial: 7950168
Drug: rHuEPO 150
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO 150 U/kg s.c. once daily for two consecutive days
Trial: 7950168
Drug: rHuEPO 150
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO 150 U/kg i.v. once daily for two consecutive days